Topical and Systemic Antivirals
Özet
Certain viral infections, particularly herpes zoster, are more prevalent and present with more complications in the elderly. In this population; the weakened immune system, the prolonged course of infections, polypharmacy and drug interaction problems and the potential toxicity of systemic antivirals are the main factors that make the management of viral infections difficult.
Referanslar
Elgart ML. Skin infections and infestations in geriatric patients. Clin Geriatr Med. 2002;18(1):89-101.
Herne K, Cirelli R, Lee P, Tyring SK. Antiviral therapy of acute herpes zoster in older patients. Drugs Aging. 1996;8(2):97-112.
Abdel-Haq N, Chearskul P, Al-Tatari H, Asmar B. New antiviral agents. Indian J Pediatr. 2006;73(4):313-21.
Tayyar R, Ho D. Herpes Simplex Virus and Varicella Zoster Virus Infections in Cancer Patients. Viruses. 2023;15(2):439.
Castro MCR, Ramos-E-Silva M. Cutaneous infections in the mature patient. Clin Dermatol. 2018;36(2):188-196.
Andrei G, Snoeck R. Advances and Perspectives in the Management of Varicella-Zoster Virus Infections. Molecules. 2021;26(4):1132.
Cohen KR, Salbu RL, Frank J, Israel I. Presentation and management of herpes zoster (shingles) in the geriatric population. P T. 2013;38(4):217-27.
Weinberg JM, Scheinfeld NS. Cutaneous infections in the elderly: diagnosis and management. Dermatol Ther. 2003;16(3):195-205.
John AR, Canaday DH. Herpes Zoster in the Older Adult. Infect Dis Clin North Am. 2017;31(4):811-826.
De Clercq E. The development of BVDU: An odyssey. Antivir Chem Chemother. 2023;31:20402066231152971.
Lilie HM, Wassilew SW. 4th international conference on varicella, herpes zoster and postherpetic neuralgia (PHN). 2001, La Jolla, California, USA. Hautarzt 2002; 53: 223–224.
Wassilew S. Brivudin compared with famciclovir in the treatment of herpes zoster: Effects in acute disease and chronic pain in immunocompetent patients. A randomized, double-blind, multinational study. J Eur Acad Dermatol Venereol 2005; 19: 47–55.
Patil A, Goldust M, Wollina U. Herpes zoster: A Review of Clinical Manifestations and Management. Viruses. 2022;14(2):192.
Kawashima M., Nemoto O., Honda M., Watanabe D., Nakayama J., Imafuku S., Kato T., Katsuramaki T., Study I. Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study. J. Dermatol. 2017;44:1219–1227.
Di Pietro A, Facciolà A, Visalli G. Herpes zoster vaccine: a protection for the elderly. Ann Ig. 2018;30(4 Supple 1):23-27.
Mwakingwe-Omari A, Lecrenier N, Naficy A, Curran D, Posiuniene I. Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies. Hum Vaccin Immunother. 2023;19(3):2278362.
Parikh R, Singer D, Chmielewski-Yee E, Dessart C. Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence. Hum Vaccin Immunother. 2023;19(3):2263979.
Weinberg JM, Vafaie J, Scheinfeld NS. Skin infections in the elderly. Dermatol Clin. 2004;22(1):51-61.
